JAPAN-CORN-STARCH
17.2.2017 01:54:37 CET | Business Wire | Press release
Japan Corn Starch Co., Ltd. (Minato-ku, Tokyo; Soichiro Kurachi, president. Hereby, “Japan Corn Starch” or “the company”), the largest corn wet miller in Japan has been pursuing excellent flavor in the increasingly diverse food industry, and conducting research to find the perfect balance of fructose and glucose in high-fructose corn syrup (HFCS), used in a variety of soft drinks. The company successfully developed and obtained patent for a new product, “HFCS 70” that maintains the body equal to fructose glucose liquid sugar used in many soft drinks while having the sharp sweetness of fructose, and is about to release the product.
Since its development 50 years ago, there were only three varieties of HFCS until this year, glucose-fructose liquid sugar, fructose-glucose liquid sugar, and high-fructose liquid sugar, commoditization of which made their differentiation difficult. However, by introducing HFCS 70 into the market, the company expects to overturn the stereotypes in the HFCS industry and create a new wind in the industry.
Japan Corn Starch’s new product, HFCS 70 maintains the body while realizing a high level of sharp sweetness. This allows the product to create a flavor different from fructose glucose liquid sugar, high fructose liquid sugar, or crystalline fructose that are mainstream in the soft drink industry, and help the development of delicious drinks with a new type of sweetness. In addition, because HFCS maintains the body while realizing a high level of sharp sweetness, it can be used in products such as highly refreshing and filling jellies.
Japan Corn Starch has obtained licenses such as the first FSSC22000 and HACCP in the industry and ISO22301, which is the international standard for business continuity management system (BCMS). Furthermore, the company has been making efforts such as radiation dose measurement of each product using high-performance equipment, and quantification of odor using odor identification devices. Thus the company is fully equipped for stable distribution of products.
As a comprehensive producer of starch-related products, Japan Corn Starch will continue its commitment to offer reliable, safe, and high quality products that cater our clients’ every need through its thoroughgoing distribution system.
About the Company
Company name: Japan Corn Starch Co., Ltd.
President: Soichiro
Kurachi
Head office: Akasaka Inter City 3F, 1-11-44 Akasaka, Minato
Ward, Tokyo, 107-0052
Tel: +81-3-5570-7000 (operator)
Fax:
+81-3-5570-7001
Mail: corn@japan-cornstarch.com
URL:
http://www.nihon-cornstarch.com/english
Founded:
1867
View source version on businesswire.com: http://www.businesswire.com/news/home/20170216006427/en/
Contact:
Japan Corn Starch Co., Ltd.
Kazuki Hashimoto, +81-566-42-3129
Public
Relations
corn@japan-cornstarch.com
http://www.nihon-cornstarch.com/english
fax:
+81-3-5570-7001
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom